Lumakras’ approval for the mCRC indication was based on data from the phase III CodeBreaK 300 study, which evaluated Lumakras plus Vectibix versus the investigator's choice of therapy in KRAS ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC ...

Lumakras was cleared by the FDA in May 2021 for KRAS G12C-mutated NSCLC patients who have received at least one prior systemic therapy, marking the culmination of a decades-long effort to bring a ...

Lumakras was approved in May by the FDA as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC), becoming the first drug against a target that was long considered ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

(RTTNews) - Amgen Inc. (AMGN), Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination therapy for the treatment of patients with KRAS G12C ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...